As one of EASYGEN’s key partners, Fresenius Kabi USA brings deep expertise in cell and gene therapy, leading the effort to develop the next generation of CAR-T therapies. Through Work Package 7, next generation CAR-T treatment, Fresenius Kabi collaborates with academic institutions to advance how we modify and quantify gene-modified T cells — translating scientific innovation into clinical reality.As an instrumentation partner, the company drives forward new systems for point-of-care delivery of CAR-T therapies, aiming to bring manufacturing, quality control, and regulatory processes closer to patients.Today, only around 20% of eligible patients receive CAR-T treatment, largely due to logistical barriers, long vein-to-vein times, and high costs. Together with #EASYGEN, Fresenius Kabi is working to change that — developing solutions that could one day make same-day treatment possible. Collaboration. Innovation. Access.That’s what EASYGEN — and its partners like Fresenius Kabi — stand for.#EASYGEN #CART #Innovation #PatientAccess #PointOfCare